Showing results (1521-1530 of 8,886) with videos related to

Sort By:
Pageof 889
European Urology|April 30, 2019
The Impact of Design and Performance in Prostate-Specific Antigen Screening: Differences Between ERSPC CentersEveline A M Heijnsdijk, Jan Adolfsson, Anssi Auvinen, et al.
European Urology|September 19, 2018
A Nomogram to Predict Significant Estimated Glomerular Filtration Rate Reduction After Robotic Partial NephrectomyAlberto Martini, Shivaram Cumarasamy, Alp Tuna Beksac, et al.
European Urology|September 22, 2018
Are We Improving Erectile Function Recovery After Radical Prostatectomy? Analysis of Patients Treated over the Last DecadePaolo Capogrosso, Emily A Vertosick, Nicole E Benfante, et al.
European Urology|September 24, 2018
Epidemiology of Renal Cell CarcinomaUmberto Capitanio, Karim Bensalah, Axel Bex, et al.
European Urology|April 13, 2019
APOBEC-mediated Mutagenesis as a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder CancerMing-Jun Shi, Xiang-Yu Meng, Philippe Lamy, et al.
European Urology|October 18, 2018
Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future DirectionsAly-Khan A Lalani, Bradley A McGregor, Laurence Albiges, et al.
European Urology|October 16, 2018
Intensive Imaging-based Follow-up of Surgically Treated Localised Renal Cell Carcinoma Does Not Improve Post-recurrence Survival: Results from a European Multicentre Database (RECUR)Saeed Dabestani, Christian Beisland, Grant D Stewart, et al.
European Urology|October 16, 2018
askMUSIC: Leveraging a Clinical Registry to Develop a New Machine Learning Model to Inform Patients of Prostate Cancer Treatments Chosen by Similar MenGregory B Auffenberg, Khurshid R Ghani, Shreyas Ramani, et al.
European Urology|October 3, 2018
The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial CancerNick van Dijk, Samuel A Funt, Christian U Blank, et al.
European Urology|October 7, 2018
Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant ChemotherapyEugene J Pietzak, Emily C Zabor, Aditya Bagrodia, et al.
Pageof 889